ProCE Banner Activity

SOLO2: Safety, HRQoL With Maintenance Olaparib in Germline BRCA-Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer

Slideset Download
Conference Coverage
No detrimental effect on HRQoL, significant improvement in patient-centered benefits with olaparib vs placebo despite higher olaparib-associated toxicity.

Released: June 13, 2017

Expiration: June 12, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology